Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2000

View Archived Issues

Favorable safety and efficacy data reported for Concerta; FDA issues approvable letter

Clinical trial of Emitasol completed

Shire buys rights to sell ulcerative colitis treatment in Europe

Antisoma temporarily halts Theragyn phase III enrollment

Clonidine may help reduce tamoxifen-induced hot flashes in breast cancer patients

Ropinirole reduces the risk of dyskinesia in early Parkinson's disease

Vertex receives USD 10 million from Aventis for new drugs targeting inflammatory diseases

Two neuroscience companies to merge

Celecoxib studies reported at DDW

News from DDW: update on Gastrimmune clinical studies

CVT-124 assessed in cirrhotic patients with ascites

FMdC and gemcitabine compared in pancreatic cancer xenograft model

Gastroduodenal effects of parecoxib assessed in the elderly

New class of microtubule assembly inhibitors discovered by the former RPR

French research team designs highly potent and selective human B1 receptor antagonists

Phase I trial of Hu1D10 continues following positive results in first lymphoma patients treated

New fusion toxin with therapeutic potential in acute-phase CML presented at ASCO

Roche withdraws application to CPMP for Tamiflu; resubmission planned in near future

Single doses of HspE7 are well tolerated and elicit specific cell-mediated immunity

Aronex reports clinical results for Atragen in APL and renal cell cancer at ASCO meeting

Potential new antidepressants under study at Welfide

Microbial metabolite discovered by Banyu to have antitumor activity

Cell adhesion inhibitors under development at Kyorin

L-Glu-L-Trp analogues with advantages over parent compound

Pfizer's new adenosine A2A receptor agonists useful for respiratory and inflammatory diseases

Epibatidine analogues with high affinity for nicotinic acetylcholine receptors

Anxiolytic agents from MS&D targeting a GABA-A receptor subunit

New inhibitors of cytokine production with a 5-aminoisoxazole moiety

CPMP recommends approval of Herceptin for treatment of metastatic breast cancer

Advantages of Specific RAAS Blockage -- Internet Webcast available to Daily Essentials readers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...